Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "solid-tumor"

103 News Found

Ipsen acquires Simcere Zaiming’s innovative ADC SIM0613
Biopharma | December 24, 2025

Ipsen acquires Simcere Zaiming’s innovative ADC SIM0613

The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.


FDA nod to Johnson & Johnson’s AKEEGA for aggressive prostate cancer
Drug Approval | December 18, 2025

FDA nod to Johnson & Johnson’s AKEEGA for aggressive prostate cancer

Patients with BRCA mutations often face aggressive disease and poor prognosis


GSK’s experimental lung cancer drug gains FDA orphan drug status
Drug Approval | December 12, 2025

GSK’s experimental lung cancer drug gains FDA orphan drug status

GSK holds exclusive global rights (excluding mainland China, Hong Kong, Macau, and Taiwan) from Hansoh Pharma to advance its development and commercialization


BioNTech and Bristol Myers Squibb report punchy early results for experimental TNBC therapy
Clinical Trials | December 11, 2025

BioNTech and Bristol Myers Squibb report punchy early results for experimental TNBC therapy

The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first


Zydus launches affordable biosimilar 'Zyrifa' for cancer-related bone complications
News | December 10, 2025

Zydus launches affordable biosimilar 'Zyrifa' for cancer-related bone complications

Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors


Kelun-Biotech and Crescent Biopharma forge strategic oncology partnership
Clinical Trials | December 09, 2025

Kelun-Biotech and Crescent Biopharma forge strategic oncology partnership

The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination


Takeda seals $1.2 billion oncology deal with Innovent Biologics
News | December 07, 2025

Takeda seals $1.2 billion oncology deal with Innovent Biologics

Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent


Kelun-Biotech’s Sac-TMT shows breakthrough results in first-line lung cancer trial
Clinical Trials | November 27, 2025

Kelun-Biotech’s Sac-TMT shows breakthrough results in first-line lung cancer trial

Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors


Merus and Halozyme collaborate to advance subcutaneous Petosemtamab development
R&D | November 18, 2025

Merus and Halozyme collaborate to advance subcutaneous Petosemtamab development

Merus has licensed Halozyme’s proprietary ENHANZE technology to develop and commercialize subcutaneous formulations of petosemtamab


ImmunoScape inks agreement with Cue Biopharma to launch next-gen cancer immunotherapy
Biopharma | November 16, 2025

ImmunoScape inks agreement with Cue Biopharma to launch next-gen cancer immunotherapy

The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies